Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
3.
Int J Cardiol ; 176(1): 86-93, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25034802

RESUMEN

OBJECTIVES: We sought to investigate the potential impact of preoperative short-term mechanical circulatory support (MCS) with extracorporeal devices on postoperative outcomes after emergency heart transplantation (HT). METHODS: We conducted an observational study of 669 patients who underwent emergency HT in 15 Spanish hospitals between 2000 and 2009. Postoperative outcomes of patients bridged to HT on short-term MCS (n=101) were compared with those of the rest of the cohort (n=568). Short-term MCS included veno-arterial extracorporeal membrane oxygenators (VA-ECMOs, n=23), and both pulsatile-flow (n=53) and continuous-flow (n=25) extracorporeal ventricular assist devices (VADs). No patient underwent HT on intracorporeal VADs. RESULTS: Preoperative short-term MCS was independently associated with increased in-hospital postoperative mortality (adjusted odds-ratio 1.75, 95% CI 1.05-2.91) and overall post-transplant mortality (adjusted hazard-ratio 1.60, 95% CI 1.15-2.23). Rates of major surgical bleeding, cardiac reoperation, postoperative infection and primary graft failure were also significantly higher among MCS patients. Causes of death and survival after hospital discharge were similar in MCS and non-MCS candidates. Increased risk of post-transplant mortality affected patients bridged on pulsatile-flow extracorporeal VADs (adjusted hazard-ratio 2.21, 95% CI 1.48-3.30) and continuous-flow extracorporeal VADs (adjusted hazard-ratio 2.24, 95% CI 1.20-4.19), but not those bridged on VA-ECMO (adjusted hazard-ratio 0.51, 95% CI 0.21-1.25). CONCLUSIONS: Patients bridged to emergency HT on short-term MCS are exposed to an increased risk of postoperative complications and mortality. In our series, preoperative bridging with VA-ECMO resulted in comparable post-transplant outcomes to those of patients transplanted on conventional support.


Asunto(s)
Bases de Datos Factuales , Tratamiento de Urgencia/efectos adversos , Circulación Extracorporea , Trasplante de Corazón/efectos adversos , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/terapia , Adulto , Estudios de Cohortes , Tratamiento de Urgencia/mortalidad , Circulación Extracorporea/mortalidad , Femenino , Estudios de Seguimiento , Trasplante de Corazón/mortalidad , Corazón Auxiliar , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/mortalidad , España/epidemiología , Factores de Tiempo , Resultado del Tratamiento
4.
Circ Heart Fail ; 6(4): 763-72, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23674362

RESUMEN

BACKGROUND: Postoperative outcomes of patients with advanced heart failure undergoing ventricular assist device implantation are strongly influenced by their preoperative Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles. We sought to investigate whether a similar association exists in patients undergoing emergency heart transplantation. METHODS AND RESULTS: By means of the Spanish National Heart Transplant Registry database, we identified 704 adult patients treated with emergency heart transplantation in 15 Spanish centers between 2000 and 2009. Post-transplant outcomes were analyzed pertaining to patient preoperative INTERMACS profiles, which were retrospectively assigned by 2 blinded cardiologists. Before transplantation, INTERMACS profile 1 (critical cardiogenic shock) was present in 207 patients, INTERMACS profile 2 (progressive decline) in 291, INTERMACS profile 3 (inotropic dependence) in 176, and INTERMACS profile 4 (resting symptoms) was present in 30 patients. In-hospital postoperative mortality rates were, respectively, 43%, 26.8%, and 18% in patients with profiles 1, 2, and 3 to 4 (P<0.001). INTERMACS 1 patients also presented the highest incidence of primary graft failure (1: 31.3%, 2: 22.3%, 3-4: 21.8%; P=0.03) and postoperative need for dialysis (1: 33.2%, 2: 18.9%, 3-4: 21.5%; P<0.001). Adjusted odds-ratios for in-hospital postoperative mortality were 4.38 (95% confidence interval, 2.51-7.66) for profile 1 versus 3 to 4, 2.49 (95% confidence interval, 1.56-3.97) for profile 1 versus 2, and 1.76 (95% confidence interval, 1.02-3.03) for profile 2 versus 3 to 4. Long-term survival after hospital discharge was not influenced by preoperative INTERMACS profiles. CONCLUSIONS: Preoperative INTERMACS profiles determine outcomes after emergency heart transplantation. Results call for a change in policies related to the management of heart transplant candidates presenting with INTERMACS profiles 1 and 2.


Asunto(s)
Circulación Asistida , Trasplante de Corazón , Corazón Auxiliar , Evaluación de Resultado en la Atención de Salud , Índice de Severidad de la Enfermedad , Adulto , Anciano , Enfermedad Crítica , Servicios Médicos de Urgencia , Femenino , Estado de Salud , Trasplante de Corazón/mortalidad , Mortalidad Hospitalaria , Humanos , Contrapulsador Intraaórtico , Masculino , Persona de Mediana Edad , Selección de Paciente , Sistema de Registros , Estudios Retrospectivos , España , Obtención de Tejidos y Órganos , Resultado del Tratamiento
6.
Rev. esp. cardiol. Supl. (Ed. impresa) ; 13(supl.E): 81e-91e, 2013. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-165970

RESUMEN

Los primeros ensayos clínicos han demostrado que la terapia celular puede mejorar el proceso de recuperación cardiaca tras la fase aguda del infarto de miocardio y la función cardiaca en la cardiopatía isquémica crónica. Sin embargo, algunos estudios han mostrado resultados contradictorios y aún existen dudas acerca de los mecanismos de acción y sobre la estrategia de tratamiento ideal para conseguir una mayor reparación cardiaca. En este capítulo se revisa la evidencia disponible actualmente, se analizan los ensayos clínicos de fases I y II y sus limitaciones, se discuten los puntos clave para el diseño de futuros estudios y se anticipa el futuro de los nuevos campos de investigación en este fascinante campo de la investigación cardiovascular traslacional (AU)


Previous clinical trials of stem cell therapy have demonstrated that the technique can promote the recovery of heart muscle after the acute phase of myocardial infarction and can improve cardiac function in chronic ischemic heart disease. However, some studies have produced conflicting results, and there are still questions about underlying mechanisms of action and about the best treatment strategy for optimizing cardiac repair. This article contains a review of recent findings in translational cardiovascular research and of the results and limitations of phase-I and -II clinical trials, discusses key issues in the design of future trials, and summarizes new areas for investigation in this fascinating field (AU)


Asunto(s)
Humanos , Infarto del Miocardio/terapia , Isquemia Miocárdica/terapia , Medicina Regenerativa/tendencias , Investigación Biomédica Traslacional/tendencias , Tratamiento Basado en Trasplante de Células y Tejidos/tendencias , Insuficiencia Cardíaca/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA